ADC Therapeutics Medical Information Hub

Find answers to your inquiries about ADC Therapeutics products and pipeline from the Medical Information team.

Product

  • Loncastuximab Tesirine
  • Other Compounds

Indication / Disease

  • DLBCL
  • Other Select Heme Tumors
  • FL
  • MZL
  • Select Solid Tumors

Media Type

  • file icon

    Scientific Response Documents

  • video play icon

    Videos

  • powperpoint slide icon

    Slides

    Investigational Loncastuximab – LOTIS Clinical Trial Program

    Medical Affairs

    Product: Loncastuximab Tesirine, Other Compounds

    Investigational Loncastuximab – LOTIS-5 Clinical Trial

    Medical Information

    Product: Loncastuximab Tesirine, Other Compounds

    Investigational Loncastuximab – LOTIS-5 Infographic Clinical Trial and Data

    Medical Affairs

    Product: Loncastuximab Tesirine, Other Compounds

    Investigational Loncastuximab – LOTIS-7 Clinical Trial

    Medical Information

    Product: Loncastuximab Tesirine, Other Compounds

    Investigational Loncastuximab – LOTIS-7 Infographic Dosing

    Medical Affairs

    Product: Loncastuximab Tesirine, Other Compounds

    Investigational Loncastuximab – NCCN Recommendation for FL

    Medical Information

    Product: Loncastuximab Tesirine

    Investigational Loncastuximab – Treatment of RR FL (IIT)

    Medical Information

    Product: Loncastuximab Tesirine

    Investigational Loncastuximab – Treatment of RR MZL (IIT)

    Medical Information

    Product: Loncastuximab Tesirine

    Investigational Pipeline – ADCT Pipeline Slide Deck

    Medical Affairs

    Product: Loncastuximab Tesirine, Other Compounds

    Loncastuximab (ZYNLONTA) – Bulky Disease and Burkitt Lymphoma

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Calculating Dose Based on ABW

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – CD19 Expression and Sequencing

    Medical Affairs

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – CD19 Expression, Response and Treatment

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Concomitant Use with Vaccines

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Cough Incidence

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Cutaneous Reactions Management Flashcard

    Medical Affairs

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Dose Response Infographic

    Medical Affairs

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Dosing and Administration

    Medical Affairs

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Drug Interactions

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Edema and Effusion Incidence & Management

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Effusion and Edema Management Flashcard

    Medical Affairs

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Extravasation Incidence and Management

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Hypersensitivity Incidence & Management

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Infection Prophylaxis

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Infusion Line of Administration

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Latex Content

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – LOTIS-1 Study

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – LOTIS-2 and Clinical Overview

    Medical Affairs

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – LOTIS-2 Study

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – LOTIS-2 Subgroup Analysis

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Maximum Dose and Final Concentration

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Mechanism of Action

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Nausea and Vomiting Incidence

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – NCCN Recommendations for B Cell Lymphomas

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Neutropenia Incidence

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Pharmacokinetics

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Premedication

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Prior & Post Radiation Use

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Prophylactic Use of Growth Factors

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Rationale for Dose Selection

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Reinitiation of Therapy after a Missed Cycle

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Renal Safety and PTLD

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Richter’s Transformation Incidence

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Skin Reactions

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Specific Gravity

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Stability with Alternative Dilution

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Storage and Stability of Vials

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Subsequent CAR-T Therapy

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Temperature Excursion Data

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Thrombocytopenia Incidence

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Tumor Lysis Syndrome Incidence

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Use Before or After Stem Cell Transplant

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Use in Elderly Patients

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Use in Overweight Obese Patients

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Use in Patients with CNS

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Use in Patients with Hepatic Impairment

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Use in Patients with p53 Mutation

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Use in Patients with Renal Impairment

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA) – Use in Pregnancy and Lactation

    Medical Information

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA)- Effusion, Edema incidence and management

    Medical Affairs

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA)- LOTIS-1 and Clinical Overview

    Medical Affairs

    Product: Loncastuximab Tesirine

    Loncastuximab (ZYNLONTA)-Rationale for ABW Calculation

    Medical Information

    Product: Loncastuximab Tesirine